0000950170-24-028832.txt : 20240308 0000950170-24-028832.hdr.sgml : 20240308 20240308183811 ACCESSION NUMBER: 0000950170-24-028832 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240306 FILED AS OF DATE: 20240308 DATE AS OF CHANGE: 20240308 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kohli Aditya CENTRAL INDEX KEY: 0001791402 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41365 FILM NUMBER: 24736102 MAIL ADDRESS: STREET 1: C/O PHATHOM PHARMACEUTICALS, INC. STREET 2: 2150 E. LAKE COOK ROAD, SUITE 800 CITY: BUFFALO GROVE STATE: IL ZIP: 60089 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HilleVax, Inc. CENTRAL INDEX KEY: 0001888012 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 HARRISON AVE, SUITE 500 CITY: BOSTON STATE: MA ZIP: 02118 BUSINESS PHONE: (617) 213-5054 MAIL ADDRESS: STREET 1: 321 HARRISON AVE, SUITE 500 CITY: BOSTON STATE: MA ZIP: 02118 4 1 ownership.xml 4 X0508 4 2024-03-06 0001888012 HilleVax, Inc. HLVX 0001791402 Kohli Aditya C/O HILLEVAX, INC., 321 HARRISON AVE, SUITE 500 BOSTON MA 02118 true false false false true Common Stock 2024-03-06 4 S false 6000 18.9501 D 837776 D Common Stock 2024-03-07 4 S false 6000 18.3688 D 831776 D Common Stock 2024-03-08 4 S false 6000 18.6598 D 825776 D The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person October 12, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices between $18.58 and $19.51. The Reporting Person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices between $17.91 and $18.92. The Reporting Person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices between $18.37 and $18.97. The Reporting Person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Paul Bavier, Attorney-in-Fact for Aditya Kohli 2024-03-08